Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma, Disorder Related to Bone Marrow Transplantation
In brief
The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated voluntary donor will help patients with advanced cutaneous T-cell lymphoma. The length of time that patients who receive the treatment remain free of disease will also be studied.
Key facts
- Study ID
- NCT00506129
- Run by
- M.D. Anderson Cancer Center
- People needed
- 33
- Starts
- 2003-09-01
- Expected to finish
- 2015-06-01
- Last updated by the study team
- 2020-12-29
Who can join
Age: any, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with pathologically proven cutaneous T-cell lymphoma (CTCL), disease stage IIB to IVB, patients must be in at least a partial response-PR (skin and lymph nodes) after receiving other non-allogeneic transplant therapy, age </= 70 years, Zubrod performance status 0 or 1, left ventricular ejection fraction >/= 50% or approved for transplant by a cardiologist, DLCO >/= 50% predicted or approved for transplant by a pulmonologist, serum creatinine </= 1.5 mg/dL, serum bilirubin < 2mg/dL. SGPT < 3 x upper limit of normal, and no previous history of allogeneic transplantation.
- Donor: HLA-compatible related (HLA-A, -B, -DRB1 matched or with one-antigen mismatch) or HLA-compatible unrelated (HLA-A, -B, -C and -DRB1 matched or with one-antigen mismatch).
You may not qualify if…
- Patients cannot have active central nervous system (CNS) disease.
Where it is running
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.